Daiichi/Sankyo Merger Leaves Future Of OTC Unit Up In The Air
This article was originally published in The Pink Sheet Daily
Executive Summary
The combined firms’ nonprescription and other non-core businesses could become independent subsidiaries or a separate company, Daiichi CEO says. Daiichi Sankyo may follow the lead of Chugai, which divested its OTC business in 2004.